“Smart investors know the biotech industry’s full of clinical-stage companies that can explode in value overnight in response to positive clinical trial results or Food and Drug Administration approvals,” notes the author of today’s article. He proceeds to highlight three biotech stocks with the potential to double – or more – this year on such announcements/approvals. For these three biotech stocks that may appeal to risk-tolerant investors – and which one the author believes is the safest bet – CLICK HERE.